1. '926 CHK1 inhibitor for administration to a patient with cancer to enhance the DNA damaging agent, wherein the administration of the CHK1 inhibitor follows the administration of the DNA damaging agent and is carried out in two doses, the first of which is administered one day after the DNA damaging agent, and the second, two days after the DNA damaging agent. 2. The SNK1 inhibitor according to claim 1 for administration to a patient with cancer to enhance the DNA damaging agent, wherein the introduction of the SNK1 inhibitor follows the introduction of the DNA damaging agent and is carried out in three doses, the first of which is administered one day after the DNA damaging agent, the second dose - two days after the DNA damaging agent, and the third dose - three days after the DNA damaging agent. 3. The CHK1 inhibitor according to claim 1, characterized in that the '926 CHK1 inhibitor is (R) -N- (4- (3-aminopiperidin-1-yl) -5-bromo-1H-pyrrole [2,3-b] pyridin-3-yl) nicotinamide 1.4. The CHK1 inhibitor according to claim 1, characterized in that the '926 CHK1 inhibitor is (R) -N- (4- (3-aminopiperidin-1-yl) -5-bromo-1H-pyrrole [2,3-b] pyridin-3-yl) isobutyramide. 5. The CHK1 inhibitor according to claim 1, characterized in that the '926 CHK1 inhibitor is (R) -N- (5-bromo-4- (3- (methylamino) piperidin-1-yl) -1H-pyrrole [2,3 -b] pyridin-3-yl) nicotinamide. 6. The CHK1 inhibitor according to claim 1, characterized in that the '926 CHK1 inhibitor is (R) -N- (4- (3-aminopiperidin-1-yl) -5-bromo-1H-pyrrole [2,3-b] pyridin-3-yl) -5-methylnicotinamide. 7. The CHK1 inhibitor according to claim 1, characterized in that the '926 CHK1 inhibitor is (R) -N- (4- (3-aminopiperidin-1-yl) -5-bromo-1H-pyrrole [2,3-b] pyridin-3-yl) piclopropanecarboxamide. 8. The CHK1 inhibitor according to claim 1, characterized in that the '926 CHK1 inhibitor is (R) -N- (4- (3-aminopiperidin-1-yl) -5-1. '926 ингибитор СНК1 для введения пациенту с раковым заболеванием для усиления ДНК-повреждающего
